The greatest burden of data on ALK fusions has been collected for lung NECs, given the relevant role in the therapeutic management of NSCLC patients, whereas for non-lung NECs, the evidence of ALK fusions/amplifications is scarce, with reports of complete lack of expression in pancreatic NETs (0/46 cases) (46). This evidence concerns the gene ALK and pancreatic neuroendocrine tumor.